ABSTRACT
BACKGROUND No definitive treatment exists for Coronavirus Disease 2019 (COVID-19). Honey and Nigella sativa (HNS) has established anti-viral properties. Hence, we investigated efficacy of HNS against COVID-19.
METHODS We conducted a multicenter-randomized-controlled-trial in COVID-19 patients. Randomized patients received either honey (1 gm/Kg/day) and Nigella sativa (80 mg/Kg/day) or placebo upto 13 days. The outcomes included symptoms alleviation, viral clearance, and 30-day mortality.
RESULTS Of 313 patients, 210 moderate and 103 severe underwent randomization. Among these 107 were assigned to HNS whereas 103 to placebo for moderate cases. For severe cases, 50 were given HNS and 53 placebo. HNS resulted in symptoms alleviation by 3 and 7 days in moderate and severe disease, respectively (Hazard Ratio [HR]: 6.11; 95% Confidence Interval [CI]: 4.23-8.84, P<0.0001 and HR: 4.04; 95% CI, 2.46-6.64, P<0.0001). HNS also cleared the virus 4 days earlier in moderate (HR: 5.53; 95% CI: 3.76-8.14, P<0.0001) and severe cases (HR: 4.32; 95% CI: 2.62-7.13, P<0.0001). HNS further led to a better clinical score on day 6 with normal activities in 63.6% (moderate, OR: 0.07; 95% CI: 0.03-0.13, P<0.0001) and 28% (severe, OR: 0.03; 95% CI: 0.01-0.09, P<0.0001) patients. A reduction in 30-day mortality among severe patients was shown with HNS (4% versus 18.87%, OR: 0.18; 95% CI: 0.02-0.92, P=0.029). No HNS-related adverse effects were observed.
CONCLUSIONS HNS improved symptoms, viral clearance and mortality in COVID-19 patients. Thus, HNS represents an affordable therapy and can be used alone or in combination with other treatments to achieve potentiating effects against COVID-19. (Funded by Smile Welfare Organization, Shaikh Zayed Medical Complex and Services Institute of Medical Sciences; NIH Clinical Trial Register number: NCT04347382.)
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04347382
Funding Statement
Funded by Smile Welfare Organization, Shaikh Zayed Medical Complex and Services Institute of Medical Sciences
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan approval ID SZH/IRB/0026/2020 and IRB Services Institute of Medical Sciences, Lahore, Pakistan approval ID IRB/2020/658/SIMS
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Joint First Author
correction of a typographical error in the dosage of honey changed from 1mg/Kg/day to 1gm/Kg/day
Data Availability
Clinical data is available as additional file and raw data can be provided on request to corresponding author
